ArticleBlood cancer journal2025

Glofitamab combined with tislelizumab in relapsed/refractory diffuse large B-cell lymphoma: a single-center pilot trial.

De Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.